You are here

  • Home
  • Archive
  • Volume 80, Issue 7
  • JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Article metrics

Article menu
Rheumatoid arthritis
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

 

Online download statistics by month:

Online download statistics by month: March 2021 to April 2025

AbstractFullPdf
Mar 2021160815601172
Apr 202116011598999
May 202110421070455
Jun 202112711260726
Jul 2021949912569
Aug 2021703688364
Sep 2021939916506
Oct 2021887860536
Nov 2021743688404
Dec 2021567551325
Jan 2022515526303
Feb 2022594569379
Mar 2022722727419
Apr 2022684677399
May 2022779767444
Jun 2022786772423
Jul 2022725709315
Aug 2022692672293
Sep 2022715713307
Oct 2022740714369
Nov 2022663647344
Dec 2022463442240
Jan 2023572544292
Feb 2023735723364
Mar 2023755716368
Apr 2023617594329
May 2023632598348
Jun 2023673657295
Jul 2023632609279
Aug 2023527503256
Sep 2023625617281
Oct 2023582543286
Nov 2023723675352
Dec 2023564485290
Jan 2024347237189
Feb 2024519456276
Mar 2024671605375
Apr 2024612563343
May 2024478414283
Jun 2024395376253
Jul 2024555502326
Aug 2024446427319
Sep 2024450417622
Oct 2024523495322
Nov 2024674640437
Dec 2024539507322
Jan 2025409379256
Feb 2025316289174
Mar 202520620898
Apr 2025257258147
Total334223207518773